Trump Administration Fills Key FDA Leadership Roles Amid Controversy

The Trump administration has permanently filled four key leadership roles at the Food and Drug Administration (FDA), including naming Heidi Overton as its commissioner. Michael Davis, a psychiatrist, will lead the Center for Drug Evaluation and Research, while Karim Mikhail, a former Merck official, will head the Center for Biologics Evaluation and Research. Bret Koplow, an attorney with over 10 years at the FDA, has been appointed director of the Center for Tobacco Products.

Jared Seehafer, an entrepreneur and executive who founded a life science software company, has been named the FDA's first deputy commissioner for technology and artificial intelligence. This newly created position underscores the administration's commitment to accelerating AI innovation and ensuring an effective regulatory framework for emerging technologies, according to the Department of Health and Human Services.

The moves aim to bring continuity to FDA leadership that has been plagued by frequent turnover and leadership departures, including President Trump's first FDA commissioner in his second term, Marty Makary, who resigned in May. Overton's confirmation would mark a significant shift at an agency viewed as less trustworthy and more politicized than in previous administrations.